CAR immune cells: design principles, resistance and the next generation
L Labanieh, CL Mackall - Nature, 2023 - nature.com
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …
[HTML][HTML] Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021
Q Wu, W Qian, X Sun, S Jiang - Journal of hematology & oncology, 2022 - Springer
Abstract The United States Food and Drug Administration (US FDA) has always been a
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
forerunner in drug evaluation and supervision. Over the past 31 years, 1050 drugs …
Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy
Messenger RNA (mRNA) has received great attention in the prevention and treatment of
various diseases due to the success of coronavirus disease 2019 (COVID‐19) mRNA …
various diseases due to the success of coronavirus disease 2019 (COVID‐19) mRNA …
Landscape of prostate-specific membrane antigen heterogeneity and regulation in AR-positive and AR-negative metastatic prostate cancer
Tumor expression of prostate-specific membrane antigen (PSMA) is lost in 15–20% of men
with castration-resistant prostate cancer (CRPC), yet the underlying mechanisms remain …
with castration-resistant prostate cancer (CRPC), yet the underlying mechanisms remain …
[PDF][PDF] TGF-β signaling in health and disease
J Massagué, D Sheppard - Cell, 2023 - cell.com
The TGF-β regulatory system plays crucial roles in the preservation of organismal integrity.
TGF-β signaling controls metazoan embryo development, tissue homeostasis, and injury …
TGF-β signaling controls metazoan embryo development, tissue homeostasis, and injury …
[HTML][HTML] The current landscape of CAR T-cell therapy for solid tumors: Mechanisms, research progress, challenges, and counterstrategies
A Daei Sorkhabi, L Mohamed Khosroshahi… - Frontiers in …, 2023 - frontiersin.org
The successful outcomes of chimeric antigen receptor (CAR) T-cell therapy in treating
hematologic cancers have increased the previously unprecedented excitement to use this …
hematologic cancers have increased the previously unprecedented excitement to use this …
[HTML][HTML] Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
V Bhatia, NV Kamat, TE Pariva, LT Wu, A Tsao… - Nature …, 2023 - nature.com
Six transmembrane epithelial antigen of the prostate 1 (STEAP1) is a cell surface antigen for
therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 …
therapeutic targeting in prostate cancer. Here, we report broad expression of STEAP1 …
Metabolic challenges and interventions in CAR T cell therapy
Chimeric antigen receptor (CAR) T cells have achieved true clinical success in treating
hematological malignancy patients, laying the foundation of CAR T cells as a new pillar of …
hematological malignancy patients, laying the foundation of CAR T cells as a new pillar of …
[HTML][HTML] CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial
A Mackensen, JBAG Haanen, C Koenecke, W Alsdorf… - Nature Medicine, 2023 - nature.com
The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid
tumors, and could be a promising treatment target. We report dose escalation results from …
tumors, and could be a promising treatment target. We report dose escalation results from …
[HTML][HTML] Progress and prospect of immunotherapy for triple-negative breast cancer
C Luo, P Wang, S He, J Zhu, Y Shi, J Wang - Frontiers in Oncology, 2022 - frontiersin.org
Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …